Go to
JCI Insight
Citations to this article
Margaret Nieborowska-Skorska, … , Stephen M. Sykes, Tomasz Skorski
Published May 8, 2017
Citation Information: J Clin Invest. 2017;127(6):2392-2406. https://doi.org/10.1172/JCI90825.
Citation Information: J Clin Invest. 2017;127(6):2392-2406. https://doi.org/10.1172/JCI90825.
Abstract
Quiescent and proliferating leukemia cells accumulate highly lethal DNA double-strand breaks that are repaired by 2 major mechanisms: BRCA-dependent homologous recombination and DNA-dependent protein kinase–mediated (DNA-PK–mediated) nonhomologous end-joining, whereas DNA repair pathways mediated by poly(ADP)ribose polymerase 1 (PARP1) serve as backups. Here we have designed a personalized medicine approach called gene expression and mutation analysis (GEMA) to identify BRCA- and DNA-PK–deficient leukemias either directly, using reverse transcription-quantitative PCR, microarrays, and flow cytometry, or indirectly, by the presence of oncogenes such as BCR-ABL1. DNA-PK–deficient quiescent leukemia cells and BRCA/DNA-PK–deficient proliferating leukemia cells were sensitive to PARP1 inhibitors that were administered alone or in combination with current antileukemic drugs. In conclusion, GEMA-guided targeting of PARP1 resulted in dual cellular synthetic lethality in quiescent and proliferating immature leukemia cells, and is thus a potential approach to eradicate leukemia stem and progenitor cells that are responsible for initiation and manifestation of the disease. Further, an analysis of The Cancer Genome Atlas database indicated that this personalized medicine approach could also be applied to treat numerous solid tumors from individual patients.
Authors
Margaret Nieborowska-Skorska, Katherine Sullivan, Yashodhara Dasgupta, Paulina Podszywalow-Bartnicka, Grazyna Hoser, Silvia Maifrede, Esteban Martinez, Daniela Di Marcantonio, Elisabeth Bolton-Gillespie, Kimberly Cramer-Morales, Jaewong Lee, Min Li, Artur Slupianek, Daniel Gritsyuk, Sabine Cerny-Reiterer, Ilona Seferynska, Tomasz Stoklosa, Lars Bullinger, Huaqing Zhao, Vera Gorbunova, Katarzyna Piwocka, Peter Valent, Curt I. Civin, Markus Muschen, John E. Dick, Jean C.Y. Wang, Smita Bhatia, Ravi Bhatia, Kolja Eppert, Mark D. Minden, Stephen M. Sykes, Tomasz Skorski
Total citations by year
Citation information
Citations to this article (52)
| Title and authors | Publication | Year |
|---|---|---|
|
Concomitant inhibition of the thioredoxin system and nonhomologous DNA repair potently sensitizes Philadelphia‐positive lymphoid leukemia to tyrosine kinase inhibitors
Komorowski L, Dabkowska A, Madzio J, Pastorczak A, Szczygiel K, Janowska M, Fidyt K, Bielecki M, Hunia J, Bajor M, Stoklosa T, Winiarska M, Patkowska E, Firczuk M |
HemaSphere | 2024 |
|
Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer
Bailey M, Morand S, Royfman R, Lin L, Singh A, Stanbery L, Walter A, Hamouda D, Nemunaitis J |
International journal of molecular sciences | 2024 |
|
Association of PARP1 Expression Levels and Clinical Parameters in Different Leukemic Subtypes With BCR::ABL1 p190+ Translocation.
DE Morais GP, Machado CB, Dias Nogueira BM, DE Pinho Pessoa FMC, DE Sousa Oliveira D, Ribeiro RM, DA Silva JBS, Seabra AD, Mello Júnior FAR, Burbano RR, Khayat AS, DE Moraes Filho MO, DE Moraes MEA, Moreira-Nunes CA |
Cancer diagnosis & prognosis | 2024 |
|
Star wars against leukemia: attacking the clones.
Toma MM, Skorski T |
Leukemia | 2024 |
|
ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias.
Golovine K, Abalakov G, Lian Z, Chatla S, Karami A, Chitrala KN, Madzo J, Nieborowska-Skorska M, Huang J, Skorski T |
Blood Cancer Journal | 2023 |
|
Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells.
Hiroki H, Ishii Y, Piao J, Namikawa Y, Masutani M, Honda H, Akahane K, Inukai T, Morio T, Takagi M |
Scientific Reports | 2023 |
|
Simultaneous Targeting of DNA Polymerase Theta and PARP1 or RAD52 Triggers Dual Synthetic Lethality in Homologous Recombination–Deficient Leukemia Cells
Sullivan-Reed K, Toma MM, Drzewiecka M, Nieborowska-Skorska M, Nejati R, Karami A, Wasik MA, Sliwinski T, Skorski T |
Molecular cancer research : MCR | 2023 |
|
PARP1 Characterization as a Potential Biomarker for BCR::ABL1 p190+ Acute Lymphoblastic Leukemia
Machado CB, da Silva EL, Ferreira WA, Pessoa FM, de Quadros AU, Fantacini DM, Furtado IP, Rossetti R, Silveira RM, de Lima SC, Mello Júnior FA, Seabra AD, Moreira EC, de Moraes Filho MO, de Moraes ME, Montenegro RC, Ribeiro RM, Khayat AS, Burbano RM, de Oliveira EH, Covas DT, de Souza LE, Moreira-Nunes CD |
Cancers | 2023 |
|
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies
A Padella, A Rorà, G Marconi, M Ghetti, G Martinelli, G Simonetti |
Journal of Hematology & Oncology | 2022 |
|
Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia
S Santis, C Monaldi, M Mancini, S Bruno, M Cavo, S Soverini |
OncoTargets and therapy | 2022 |
|
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia
M Baer, A Kogan, S Bentzen, T Mi, R Lapidus, V Duong, A Emadi, S Niyongere, C O'Connell, B Youngblood, S Baylin, F Rassool |
Clinical cancer research | 2022 |
|
Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system
T Nguyen, M Tamai, D Harama, K Kagami, S Kasai, A Watanabe, K Akahane, K Goi, T Inukai |
International Journal of Hematology | 2022 |
|
Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality
Le BV, Podszywałow-Bartnicka P, Piwocka K, Skorski T |
Cancers | 2022 |
|
DNA Repair Genes Polymorphisms: Impact on Acute Myeloid Leukemia Patients Outcome
Aref S, El Menshawy N, Abou Zeid T, Gouda E, Abdel Aziz N |
Asian Pacific Journal of Cancer Prevention | 2022 |
|
Synergistic effect of combined PI3 kinase inhibitor and PARP inhibitor treatment on BCR/ABL1-positive acute lymphoblastic leukemia cells.
Hiroki H, Akahane K, Inukai T, Morio T, Takagi M |
International Journal of Hematology | 2022 |
|
DNA polymerase θ protects leukemia cells from metabolically induced DNA damage
Vekariya U, Toma M, Nieborowska-Skorska M, Le BV, Caron MC, Kukuyan AM, Sullivan-Reed K, Podszywalow-Bartnicka P, Chitrala KN, Atkins J, Drzewiecka M, Feng W, Chan J, Chatla S, Golovine K, Jelinek J, Sliwinski T, Ghosh J, Matlawska-Wasowska K, Chandramouly G, Nejati R, Wasik M, Sykes SM, Piwocka K, Hadzijusufovic E, Valent P, Pomerantz RT, Morton G, Childers W, Zhao H, Paietta EM, Levine RL, Tallman MS, Fernandez HF, Litzow MR, Gupta GP, Masson JY, Skorski T |
Blood | 2022 |
|
PARP Inhibitors and Haematological Malignancies—Friend or Foe?
KA Skelding, LF Lincz |
Cancers | 2021 |
|
Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment
M Valikhani, E Rahimian, SE Ahmadi, R Chegeni, M Safa |
Experimental Hematology and Oncology | 2021 |
|
Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway
A Padella, MC Fontana, G Marconi, E Fonzi, E Petracci, A Ferrari, C Baldazzi, C Papayannidis, AG Rorá, N Testoni, G Castellani, T Haferlach, G Martinelli, G Simonetti |
Blood Cancer Journal | 2021 |
|
Recurrent deletions in clonal hematopoiesis are driven by microhomology-mediated end joining
T Feldman, A Bercovich, Y Moskovitz, N Chapal-Ilani, A Mitchell, JJ Medeiros, T Biezuner, N Kaushansky, MD Minden, V Gupta, M Milyavsky, Z Livneh, A Tanay, LI Shlush |
Nature Communications | 2021 |
|
TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors
S Maifrede, BV Le, M Nieborowska-Skorska, K Golovine, K Sullivan-Reed, WM Dunuwille, J Nacson, M Hulse, K Keith, J Madzo, LB Caruso, Z Gazze, Z Lian, A Padella, KN Chitrala, BA Bartholdy, K Matlawska-Wasowska, DD Marcantonio, G Simonetti, G Greiner, SM Sykes, P Valent, EM Paietta, MS Tallman, HF Fernandez, MR Litzow, MD Minden, J Huang, G Martinelli, GS Vassiliou, I Tempera, K Piwocka, N Johnson, GA Challen, T Skorski |
Cancer research | 2021 |
|
PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword
CM Csizmar, AN Saliba, EM Swisher, SH Kaufmann |
Cancers | 2021 |
|
PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome
C Kontandreopoulou, P Diamantopoulos, D Tiblalexi, N Giannakopoulou, N Viniou |
Blood Advances | 2021 |
|
TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment
BV Le, P Podszywalow-Bartnicka, S Maifrede, K Sullivan-Reed, M Nieborowska-Skorska, K Golovine, JC Yao, R Nejati, KQ Cai, LB Caruso, J Swatler, M Dabrowski, Z Lian, P Valent, EM Paietta, RL Levine, HF Fernandez, MS Tallman, MR Litzow, J Huang, GA Challen, D Link, I Tempera, MA Wasik, K Piwocka, T Skorski |
Cell Reports | 2020 |
|
Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage—Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities
L Komorowski, K Fidyt, E Patkowska, M Firczuk |
International journal of molecular sciences | 2020 |
|
Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes
J Stetka, J Gursky, JL Velasquez, R Mojzikova, P Vyhlidalova, L Vrablova, J Bartek, V Divoky |
Cancers | 2020 |
|
Maximizing Breast Cancer Therapy with Awareness of Potential Treatment‐Related Blood Disorders
HG Kaplan, GS Calip, JA Malmgren |
The oncologist | 2020 |
|
Repair of G1 induced DNA double-strand breaks in S-G2/M by alternative NHEJ
W Yu, C Lescale, L Babin, M Bedora-Faure, H Lenden-Hasse, L Baron, C Demangel, J Yelamos, E Brunet, L Deriano |
Nature Communications | 2020 |
|
Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia
E Hewlett, M Toma, K Sullivan-Reed, J Gordon, T Sliwinski, A Tulin, WE Childers, T Skorski |
Medicinal Chemistry Research | 2020 |
|
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
S Boussios, C Abson, M Moschetta, E Rassy, A Karathanasi, T Bhat, F Ghumman, M Sheriff, N Pavlidis |
Drugs in R & D | 2020 |
|
Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
S Boussios, M Moschetta, P Karihtala, EP Samartzis, M Sheriff, G Pappas-Gogos, MA Ozturk, M Uccello, A Karathanasi, M Tringos, E Rassy, N Pavlidis |
Annals of translational medicine | 2020 |
|
PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.
Fritz C, Portwood SM, Przespolewski A, Wang ES |
Blood Reviews | 2020 |
|
Clinical utility of custom-designed NGS panel testing in pediatric tumors
LF Surrey, SP MacFarland, F Chang, K Cao, KS Rathi, GT Akgumus, D Gallo, F Lin, A Gleason, P Raman, R Aplenc, R Bagatell, J Minturn, Y Mosse, M Santi, SK Tasian, AJ Waanders, M Sarmady, JM Maris, SP Hunger, MM Li |
Genome Medicine | 2019 |
|
Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD
AJ Dellomo, MR Baer, FV Rassool |
Cancer Letters | 2019 |
|
Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes
I Faraoni, MI Consalvo, F Aloisio, E Fabiani, M Giansanti, FD Cristino, G Falconi, L Tentori, AD Veroli, P Curzi, L Maurillo, P Niscola, F Lo-Coco, G Graziani, MT Voso |
Cancers | 2019 |
|
RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies
Toma, SR, Śliwiński, Skorski |
Cancers | 2019 |
|
Inhibition of the mutated c-KIT kinase in AML1-ETO–positive leukemia cells restores sensitivity to PARP inhibitor
M Nieborowska-Skorska, EM Paietta, RL Levine, HF Fernandez, MS Tallman, MR Litzow, T Skorski |
Blood Advances | 2019 |
|
Can synthetic lethality approach be used with DNA repair genes for primary and secondary MDS?
HL Junior, RT de Oliveira, D de Paula Borges, MB Costa, IR Farias, AW dos Santos, SM Magalhães, RF Pinheiro |
Medical Oncology | 2019 |
|
Enhanced Kat3A/Catenin transcription: a common mechanism of therapeutic resistance
A Bild, JL Teo, M Kahn |
2019 | |
|
Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice
CB DeStefano, CS Hourigan |
Therapeutic Advances in Hematology | 2018 |
|
Targeting Cancer Stem Cells to Overcome Chemoresistance
T Nunes, D Hamdan, C Leboeuf, ME Bouchtaoui, G Gapihan, T Nguyen, S Meles, E Angeli, P Ratajczak, H Lu, MD Benedetto, G Bousquet, A Janin |
International journal of molecular sciences | 2018 |
|
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors
S Maifrede, M Nieborowska-Skorska, K Sullivan, Y Dasgupta, P Podszywalow-Bartnicka, BV Le, M Solecka, Z Lian, EA Belyaeva, A Nersesyan, MM Machnicki, M Toma, N Chatain, M Rydzanicz, H Zhao, J Jelinek, K Piwocka, T Sliwinski, T Stoklosa, R Ploski, T Fischer, SM Sykes, S Koschmieder, L Bullinger, P Valent, M Wasik, J Huang, T Skorski |
Blood | 2018 |
|
PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions
P Podszywalow-Bartnicka, S Maifrede, BV Le, M Nieborowska-Skorska, K Piwocka, T Skorski |
Leukemia & Lymphoma | 2018 |
|
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
K Sullivan-Reed, E Bolton-Gillespie, Y Dasgupta, S Langer, M Siciliano, M Nieborowska-Skorska, K Hanamshet, EA Belyaeva, AJ Bernhardy, J Lee, M Moore, H Zhao, P Valent, K Matlawska-Wasowska, M Müschen, S Bhatia, R Bhatia, N Johnson, MA Wasik, AV Mazin, T Skorski |
Cell Reports | 2018 |
|
T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system
M Tamai, T Inukai, S Kojika, M Abe, K Kagami, D Harama, T Shinohara, A Watanabe, H Oshiro, K Akahane, K Goi, E Sugihara, S Nakada, K Sugita |
Scientific Reports | 2018 |
|
Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage
LB Caruso, KA Martin, E Lauretti, M Hulse, M Siciliano, LN Lupey-Green, A Abraham, T Skorski, I Tempera |
Oncotarget | 2018 |
|
Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia
M Nieborowska-Skorska, S Maifrede, M Ye, M Toma, E Hewlett, J Gordon, BV Le, T Sliwinski, H Zhao, K Piwocka, P Valent, AV Tulin, W Childers, T Skorski |
Leukemia & Lymphoma | 2018 |
|
Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
I Faraoni, G Graziani |
Cancers | 2018 |
|
Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent
M Toma, M Witusik-Perkowska, M Szwed, R Stawski, J Szemraj, M Drzewiecka, M Nieborowska-Skorska, M Radek, P Kolasa, K Matlawska-Wasowska, T Sliwinski, T Skorski |
Oncotarget | 2018 |
|
Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms
M Nieborowska-Skorska, S Maifrede, Y Dasgupta, K Sullivan, S Flis, BV Le, M Solecka, EA Belyaeva, L Kubovcakova, M Nawrocki, M Kirschner, H Zhao, JT Prchal, K Piwocka, AR Moliterno, M Wasik, S Koschmieder, TR Green, RC Skoda, T Skorski |
Blood | 2017 |
|
Drugging DNA repair to target T-ALL cells
Y Dasgupta, K Golovine, M Nieborowska-Skorska, L Luo, K Matlawska-Wasowska, CG Mullighan, T Skorski |
Leukemia & Lymphoma | 2017 |
|
MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs
S Maifrede, E Martinez, M Nieborowska-Skorska, DD Marcantonio, M Hulse, BV Le, H Zhao, K Piwocka, I Tempera, SM Sykes, T Skorski |
Blood Advances | 2017 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)